Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development

Dow Jones

Yesterday

Sionna Therapeutics will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment.

The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs and other cost-cutting measures, including discontinuing investments into a separate drug candidate, will provide a cash runway through the second half of 2029, the company said.

Sionna said it expects to incur restructuring and other charges of around $6.4 million. The restructuring is expected to be substantially complete by the end of the third quarter, with cash payments continuing through the fourth quarter.

The company expects to retain the core capabilities to advance the combination of SION-451 and SION-2222. The phase 2a trial is expected to launch in the first quarter of 2027.

Shares fell 4% to $7.93 after-hours on Monday.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/2667522695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667522695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667522695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667522695","market":"fut","top_or_hot":-1,"title":"Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SION\">Sionna Therapeutics</a> will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment. \n</p>\n<p>\n  The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs and other cost-cutting measures, including discontinuing investments into a separate drug candidate, will provide a cash runway through the second half of 2029, the company said. \n</p>\n<p>\n  Sionna said it expects to incur restructuring and other charges of around $6.4 million. The restructuring is expected to be substantially complete by the end of the third quarter, with cash payments continuing through the fourth quarter. \n</p>\n<p>\n  The company expects to retain the core capabilities to advance the combination of SION-451 and SION-2222. The phase 2a trial is expected to launch in the first quarter of 2027. \n</p>\n<p>\n  Shares fell 4% to $7.93 after-hours on Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-15 04:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SION\">Sionna Therapeutics</a> will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment. \n</p>\n<p>\n  The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs and other cost-cutting measures, including discontinuing investments into a separate drug candidate, will provide a cash runway through the second half of 2029, the company said. \n</p>\n<p>\n  Sionna said it expects to incur restructuring and other charges of around $6.4 million. The restructuring is expected to be substantially complete by the end of the third quarter, with cash payments continuing through the fourth quarter. \n</p>\n<p>\n  The company expects to retain the core capabilities to advance the combination of SION-451 and SION-2222. The phase 2a trial is expected to launch in the first quarter of 2027. \n</p>\n<p>\n  Shares fell 4% to $7.93 after-hours on Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2667522695","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667522695","pubTimestamp":1789417680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sionna Therapeutics will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment.The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs and other cost-cutting measures, including discontinuing investments into a separate drug candidate, will provide a cash runway through the second half of 2029, the company said.Sionna said it expects to incur restructuring and other charges of around $6.4 million. The restructuring is expected to be substantially complete by the end of the third quarter, with cash payments continuing through the fourth quarter.The company expects to retain the core capabilities to advance the combination of SION-451 and SION-2222. The phase 2a trial is expected to launch in the first quarter of 2027.Shares fell 4% to $7.93 after-hours on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SION":"Sionna Therapeutics"},"translate_title":"Sionna Therapeutics 将裁员 46%，专注于囊性纤维化药物开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SION":1.5},"content_text":"Sionna Therapeutics will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment. \n\n\n  The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs and other cost-cutting measures, including discontinuing investments into a separate drug candidate, will provide a cash runway through the second half of 2029, the company said. \n\n\n  Sionna said it expects to incur restructuring and other charges of around $6.4 million. The restructuring is expected to be substantially complete by the end of the third quarter, with cash payments continuing through the fourth quarter. \n\n\n  The company expects to retain the core capabilities to advance the combination of SION-451 and SION-2222. The phase 2a trial is expected to launch in the first quarter of 2027. \n\n\n  Shares fell 4% to $7.93 after-hours on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}